Board


Dr Peter Finan, Chairman

Dr Peter Finan, Chairman

Dr Peter Finan is Partner at Epidarex Capital and currently serves on the board of Clyde Bioscienes, Caldan Therapeutics, Enterprise Therpeutics and Topas Therapeutics. Prior to joining Epidarex, Dr Finan was Global Head of the Respiratory Disease Area and Site Head for the Novartis Institute of BioMedical Research in the United Kingdom. He is a former Executive Director of the Novartis Developmental and Molecular Pathways Platform based in Cambridge, Massachusetts. Earlier in his career, Dr Finan worked at Cancer Research UK and the Yamanouchi Research Institute (now Astellas). Dr Finan holds a BSc and PhD in Biochemistry and Molecular Biology from the University of Leeds.

Dr John Ford, Chief Executive Officer

Dr John Ford, Chief Executive Officer

Dr John Ford has more than 18 years of ion channel, drug discovery and development experience. As a successful biotechnology entrepreneur he co-founded Xention (CSO), Ario Pharma (CEO) and Metrion Biosciences (co-owner). At Xention he was responsible for the Kv1.5 ion channel atrial fibrillation project which was partnered to Servier (up to 120M EUR). Recently, he was a member of the Executive Team at Dezima (COO) that developed TA-8995 for dyslipidaemia (Phase 2b study published in The Lancet) and sold the company to Amgen ($300M upfront, potential deal size of US$1.55bn + royalties). Previous positions include Team Leader for Receptors and Channel Drug Discovery at BioFocus (now owned by Charles River). Dr Ford holds a BSc and Ph.D. in Biochemistry and Molecular Biology from the University of Leeds.

Dr. Liz Roper, Investor Director

Dr. Liz Roper, Investor Director

Dr Liz Roper is Partner at Epidarex Capital Capital and currently serves on the board of Edinburgh Molecular Imaging, Caldan Therapeutics, Enterprise Therapeutics and Nodthera. She has more than 15 years experience in the Life Science and Healthcare industry. Prior to joining Epidarex, Dr Roper was the Head of Business Development at Chroma Therapeutics, an Oxford-based venture-backed drug discovery and development company focused on inflammatory disorders and oncology. She is a former executive with the Life Science venture capital team at the Investments Division of The Wellcome Trust and also a former member of the Life Science team at Atlas Ventures, London. Dr Roper holds a BSc in Biochemistry (1st class) from the University College Cork, and a PhD from the Imperial Cancer Research Fund.

Dr David Morris MD, Investor Director

Dr David Morris MD, Investor Director

David is a Venture Partner at NVF in San Francisco, CA, USA. Prior to joining NVF, he held multiple leadership roles in the Novartis Pharmaceuticals development organization including the Development Franchise Head of Respiratory, Development Franchise Head of Primary Care and, most recently, Global Head of Clinical Operations, Analytics and Regions where he was responsible for clinical trials operations and monitoring. Prior to joining Novartis in 2009, David worked in drug discovery and translational medicine at Roche in Palo Alto, California. Before joining industry, he was a faculty member at Yale University Medical School and, prior to that, the University of California, San Francisco (UCSF) Medical School.

David received his Bachelors and Medical Degrees with distinction from the University of Rochester Medical School and trained in internal medicine at the Massachusetts General Hospital and in Pulmonary and Critical Care Medicine at UCSF. He did his postdoctoral research training at the Lung Biology Center and Cardiovascular Research Institute at UCSF.

Dr Alex Mayweg, Investor Director

Dr Alex Mayweg, Investor Director

Alexander Mayweg, Ph.D., is a Partner at Versant. Alex is an accomplished leader in pharmaceutical drug discovery and medicinal chemistry across Europe, the U.S. and Asia.

Alex joined Versant in 2016 from Roche where he served as global head of chemistry. He brings to Versant deep operating capabilities, having led several successful therapeutics programs within Roche Pharma Research and Early Development.

Prior to Roche, Alex earned a Ph.D. in organic chemistry at Oxford University, followed by post-doctorate training at Stanford University. His undergraduate degree was in chemistry from the Imperial College of Science and Technology in London.

Dr Gert-Jan Mulder MD, Investor Director

Dr Geert-Jan Mulder MD, Investor Director

Geert-Jan co-founded Forbion in 2006 and is currently the Managing Partner. Geert-Jan currently serves on several boards including Promedior (closed an option deal with Bristol-Myers Squibb for a total deal value of up to USD 1.25 billion), AM-Pharma (closed an option deal with Pfizer for a total deal value of up to USD 600 million), Exosome, Sanifit, NeRRe and KaNDy. In addition to his portfolio management activities, Geert-Jan closely works with management teams of various Forbion portfolio companies on clinical development strategies and regulatory matters.

Prior to Forbion, Geert-Jan was an Investment Director at ABN AMRO Capital Life Sciences (Forbion’s predecessor). Before that, at Byk Gulden (now Takeda) he served as a Clinical Research Manager, where his group was responsible for design and execution of early and late stage clinical trials forming the basis for two global product registrations: Daxas® and Alvesco® in fields of COPD and asthma. For both products he was a member of the Global Medical Marketing group.

Geert-Jan received his Medical Degree from the University of Utrecht (NL), spent two years of residency in Obstetrics and Gynaecology at the University Medical Centre of Utrecht and is a certified Pharmaceutical Physician

Dr Bobby Soni, Investor Director

Dr Bobby Soni, Investor Director

Bobby is currently Life Science Partner at IP Group plc. He joined Touchstone Innovations (now IP Group) in 2015 from Novo Seeds, the early stage investment arm of Novo AS where he worked as Investment Director. Bobby has 17 years' experience in the Life Science industry covering drug development, business development and venture capital investment. In addition to Enterprise Therapeutics, he is a Non-Executive Director of Storm Therapeutics, Artios Pharma, Pulmocide, Autifony, Oxular, and Mission Therapeutics.

Bobby holds a PhD in Biology from the University of Virginia and an undergraduate degree in Biochemistry from the University of Rochester.